CEBPA and acute myeloid leukemia: The CEBPA‐bZIP mutation (reflecting its favorable prognosis) was notably more prevalent in the UAMOCS3 group within the ihCAMs‐AML cohort, which also aligns with the findings from the TCGA‐LAML dataset (Fig. 3B).